Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors

Published:2002-12-01 Issue:12 Volume:40 Page:580-581
ISSN:0946-1965
Container-title:Int. Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:CP

Author:

Strumberg D.,Voliotis D.,Moeller J.-G.,Hilger R.A.,Richly H.,Kredtke S.,Beling C.,Scheulen M.E.,Seeber S.

Publisher

Dustri-Verlgag Dr. Karl Feistle

Subject

Pharmacology (medical),Pharmacology

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell Signaling and Translational Developmental Therapeutics;Reference Module in Biomedical Sciences;2021

2. OBSOLETE: Cell Signaling and Translational Developmental Therapeutics;Reference Module in Chemistry, Molecular Sciences and Chemical Engineering;2021

3. Not the comfy chair! Cancer drugs that act against multiple active sites;Expert Opinion on Therapeutic Targets;2019-11-02

4. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors;The Oncologist;2018-08-20

5. Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients;European Journal of Drug Metabolism and Pharmacokinetics;2017-10-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP